海杰亚(北京)医疗器械有限公司 logo — Innovative cancer treatments for lung, liver, breast, and ki...

海杰亚(北京)医疗器械有限公司

Innovative cancer treatments for lung, liver, breast, and kidney diseases with advanced micro-invasive and Cryo-HITTM technology.

Founded 2010 19 employees Series D Total: $628.00M Biopharma, Biotechnology +1

General Information

Company Name 海杰亚(北京)医疗器械有限公司
Founded Year 2010
Employees 19
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with 海杰亚(北京)医疗器械有限公司. To contact 海杰亚(北京)医疗器械有限公司, visit hygeamed.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About 海杰亚(北京)医疗器械有限公司

Hygea Medical Technology is a biopharma company founded in 2010 that specializes in offering innovative cancer therapies for lung, liver, breast, and kidney diseases. The company is committed to advancing its micro-invasive techniques and Cryo-HITTM technology. Their most recent funding round, a CNY100.00M Series D investment, took place on 15 February 2023 with participation from Gaorong Capital, In Capital, Yueyin Venture Capital, Acusea/Huiyuan Capital, 深圳市联合利丰供应链管理有限公司, MeiHong Fund, Rongquan Capital, and Qiandao Fund. The company's focus on innovative cancer treatments using advanced micro-invasive and Cryo-HITTM technology positions it well within the healthcare and biotechnology industries.

Taxonomy: biopharma, oncology, cancer therapies, lung cancer, liver cancer, breast cancer, kidney cancer, micro-invasive techniques, Cryo-HITTM technology, innovation, biopharmaceuticals, oncology treatments, oncology research, disease targeting

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series D CNY100.00M 8
Gaorong Capital, In Capital +6
15 Feb 2023
Series C CNY500.00M -
26 Apr 2021
Series B $28.00M 2
Jianxing Medical Fund, Kunying Capital
06 Dec 2019

海杰亚(北京)医疗器械有限公司 Alternatives & Competitors

View All Alternatives
海杰亚(北京)医疗器械有限公司 vs

Developing therapeutics for diseases with impaired kidney function

Series C
35 employees
Biopharma, Biotechnology
海杰亚(北京)医疗器械有限公司 vs

Advancing cancer treatment through innovative therapeutics targeting cell membranes.

Venture round
23 employees
Biotechnology, Health Care
海杰亚(北京)医疗器械有限公司 vs

Innovative solutions for minimally invasive emphysema treatment with a pioneering lung volume reduct...

Venture round
Biotechnology, Health Care

FAQ About 海杰亚(北京)医疗器械有限公司

Innovative cancer treatments for lung, liver, breast, and kidney diseases with advanced micro-invasive and Cryo-HITTM technology.
海杰亚(北京)医疗器械有限公司 was founded in 2010.
海杰亚(北京)医疗器械有限公司 operates in Biopharma, Biotechnology and Health Care. Its work centres on biopharma, oncology, cancer therapies and lung cancer.
海杰亚(北京)医疗器械有限公司 has approximately 19 employees.
海杰亚(北京)医疗器械有限公司 has completed 3 funding rounds, raising a total of $628.00M. The latest funding stage is Series D.
Top alternatives and competitors to 海杰亚(北京)医疗器械有限公司 include ENYO Pharma, AbilityPharma, PneumRx, ImmuneWorks, Rznomics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
海杰亚(北京)医疗器械有限公司 and ENYO Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for 海杰亚(北京)医疗器械有限公司, https://bouncewatch.com/company/hygea-medical-technology, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes